Back to MRKView full pipeline
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
0 competitors in Moderate to Severe Psoriasis
View Full LandscapeDrug Information
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Regulatory Approvals
EMA9/20/2004
Raptiva
Treatment of adult patients with moderate to severe chronic plaque psoriasis who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and PUVA (see section 5.1 - Clinical Efficacy).
View on EMADrug Science
Mechanism of action & safety profile
Related Pipeline
MK-8748Phase 3
Diabetic Retinopathy
alendronate with cholecalciferolPhase 3
Osteoporosis
Simvastatin 20 mg dailyPhase 3
Cardiovascular Disease
EpinephrinePhase 3
Malignant Neoplasms of Male Genital Organs
9 valent human papillomavirus vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, 58)Phase 3
HPV Positive Oropharyngeal Squamous Cell Carcinoma
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts